A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
← catalyst calendarNCT06082037 · readout in 894 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Meiji Seika Pharma Co., Ltd..
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
180estimated
Sites
79
Countries
Australia, Austria, Belgium +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-10 | actual | When the study began enrolling |
| Primary completion | 2029-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lung Transplant Rejection
Interventions
- Drug: Belumosudil — also filed as REZUROCK
- Drug: Azithromycin
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline to Week 26 in forced expiratory volume in 1 second (FEV1)
measured Baseline to Week 26
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed